We are a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.
Company Details
- Employees
- 66
- Founded
- -
- Address
- Carlsbad, Ca 92011, Us
- in****@****ntx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- designtx.com
- HQ
- Carlsbad, CA
Design Therapeutics Questions
Design Therapeutics's website is designtx.com
Design Therapeutics's LinkedIn profile is https://www.linkedin.com/company/designtx
Design Therapeutics has
66 employees.
View email and phone details for 66
employees at Design Therapeutics.
Design Therapeutics's industry is
Biotechnology Research
Design Therapeutics's top competitors are
Neomorph, Inc.,
Neurocrine Biosciences,
Adarx Pharmaceuticals Inc.,
Capstan Therapeutics,
Tarsus Pharmaceuticals, Inc.,
Ars Pharmaceuticals, Inc.,
Vtv Therapeutics,
Vividion Therapeutics, Inc.,
Ionis Pharmaceuticals, Inc.,
Vertex Pharmaceuticals.
Design Therapeutics's support email address is info@designtx.com
Design Therapeutics's categories are Biotechnology Research
Design Therapeutics's founding year is 2017
